###begin article-title 0
###xml 60 68 <span type="species:ncbi:9606">Patients</span>
Calpain-10 Expression Is Elevated in Pancreatic Islets from Patients with Type 2 Diabetes
###end article-title 0
###begin p 1
Conceived and designed the experiments: CAL LG SDG RL. Performed the experiments: CAL SDG RL. Analyzed the data: CAL RL. Contributed reagents/materials/analysis tools: CAL LG SDG RL. Wrote the paper: CAL LG SDG RL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 499 505 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
Calpain-10 was the first gene to be identified influencing the risk of type 2 diabetes (T2D) by positioning cloning. Studies in beta-cell lines and rodent islets suggest that calpain-10 may act as a regulator of insulin secretion. However, its role in human pancreatic islets remains unclear. The aim of this study was to examine if calpain-10 expression is altered in islets from patients with T2D and if the transcript level correlates with insulin release. We also tested if polymorphisms in the CAPN10 gene are associated with gene expression and insulin secretion in vitro.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 536 537 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 637 638 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 741 742 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 608 616 <span type="species:ncbi:9606">patients</span>
Calpain-10 mRNA expression was analysed in human pancreatic islets from 34 non-diabetic and 10 T2D multi-organ donors. CAPN10 SNP-43 and SNP-44 were genotyped and related to gene expression and insulin release in response to glucose, arginine and glibenclamide. The mRNA level of calpain-10 was elevated by 64% in pancreatic islets from patients with T2D compared with non-diabetic donors (P = 0.01). Moreover, the calpain-10 expression correlated positively with arginine-stimulated insulin release in islets from non-diabetic donors (r = 0.45, P = 0.015). However, this correlation was lost in islets from patients with T2D (r = 0.09; P = 0.8). The G/G variant of SNP-43 was associated with reduced insulin release in response to glucose (P</=0.04) in non-diabetic donors.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
While calpain-10 expression correlates with insulin release in non-diabetic human islets, this correlation is lost in T2D suggesting that a stimulatory effect of calpain-10 could be lost in patients with T2D.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 328 331 325 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Frayling1">[1]</xref>
###xml 403 409 400 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 454 457 451 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Horikawa1">[2]</xref>
###xml 551 554 548 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Tsuchiya1">[3]</xref>
###xml 556 559 553 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Cox1">[4]</xref>
###xml 561 564 558 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Rasmussen1">[5]</xref>
###xml 566 569 563 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Evans1">[6]</xref>
###xml 719 722 716 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Croall1">[7]</xref>
###xml 805 808 802 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Sreenan1">[8]</xref>
###xml 810 813 807 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Carlsson1">[9]</xref>
###xml 815 819 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-OrhoMelander1">[10]</xref>
###xml 821 825 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Baier1">[11]</xref>
###xml 827 831 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Zhou1">[12]</xref>
###xml 833 837 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Parnaud1">[13]</xref>
###xml 839 843 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Marshall1">[14]</xref>
###xml 845 849 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Tripathy1">[15]</xref>
###xml 851 855 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Johnson1">[16]</xref>
###xml 893 899 890 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 987 990 984 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Carlsson1">[9]</xref>
###xml 992 996 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Baier1">[11]</xref>
###xml 998 1002 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Carlsson2">[17]</xref>
###xml 1373 1379 1370 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 1117 1122 <span type="species:ncbi:9606">human</span>
###xml 1446 1451 <span type="species:ncbi:9606">human</span>
###xml 1536 1541 <span type="species:ncbi:9606">human</span>
Impaired insulin secretion from pancreatic beta-cells together with insulin resistance in peripheral tissues represent hallmarks of type 2 diabetes (T2D). The disease develops as a conspiracy between the environment and the genetic background. Indeed, common variants in a number of genes have recently been associated with T2D [1]. However, the first gene to be linked to T2D by positional cloning was CAPN10 encoding for a cystein protease, calpain-10 [2] and polymorphisms in this gene have been associated with T2D in some but not all populations [3], [4], [5], [6]. Calpains are calcium-dependent intracellular nonlysosomal proteases that can hydrolyze substrates important in calcium-regulated signaling pathways [7]. Calpain-10 has been suggested to influence both insulin secretion and resistance [8], [9], [10], [11], [12], [13], [14], [15], [16]. Furthermore, common variants in the CAPN10 gene have been associated with transcript levels in skeletal muscle and adipose tissue [9], [11], [17]. Although great efforts have been made to understand the role of calpain-10 in T2D its function and regulation in human pancreatic islets remain to be determined. The aims of the present study were therefore to 1) analyze calpain-10 expression in pancreatic islets from multi-organ donors with and without T2D, 2) examine if two polymorphisms (SNP-43 and SNP-44) in the CAPN10 gene are associated with gene expression and insulin secretion in human islets and 3) test if calpain-10 expression is associated with insulin secretion in human islets.
###end p 9
###begin title 10
Methods
###end title 10
###begin title 11
Subjects
###end title 11
###begin p 12
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Ling1">[18]</xref>
The characteristics of the non-diabetic and T2D multi-organ donors, whose pancreases have been processed for islet preparations, were presented previously [18]. The donors, whose islets were included in the present study, had the following characteristics; 10 T2D donors, 5 males and 5 females, age = 66.5+/-2.8 years and BMI = 26.6+/-1.1 kg/m2 and 47 non-diabetic donors, 29 males and 18 females, age = 52.7+/-2.4 years and BMI = 24.8+/-0.6. Calpain 10 mRNA expression was analysed in islets from all T2D donors and 34 of the non-diabetic donors. Pancreases were obtained according to the Italian National regulation and processed with the approval of the regional Ethics Committee. The donor before death or her/his relatives upon admission to Intensive Care Unit (ICU) had given their willingness to donate organs and/or tissues.
###end p 12
###begin title 13
###xml 11 16 <span type="species:ncbi:9606">human</span>
Studies of human pancreatic islets
###end title 13
###begin p 14
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-DelGuerra1">[19]</xref>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Marchetti1">[20]</xref>
Isolated pancreatic islets were prepared by collagenase digestion and density gradient purification [19]. After isolation, islets were cultured free floating in M199 culture medium (Sigma-Aldrich) at 5.5 mmol/l glucose concentration (basal condition) and studied within 3 days from isolation. Cell viability, measured by trypan blue exclusion, was higher than 90% in control and diabetic islets after 3 days in culture. Islet cell death was assessed by Cell Death Detection ELISA-plus assay (Roche Diagnostics, Milan, Italy) as previously described [20]. This assay evaluates cytoplasmic histone-associated DNA fragments.
###end p 14
###begin title 15
Insulin secretion study
###end title 15
###begin p 16
###xml 65 69 65 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-DelGuerra1">[19]</xref>
###xml 896 903 876 883 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 896 903 876 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006558-t001"><bold>Table 1</bold></xref>
Insulin secretion studies were performed as previously described [19]. Following a 45 min pre-incubation period at 3.3 mmol/l glucose, groups of 30 islets of comparable size were kept at 37degreesC for 45 min in Krebs-Ringer bicarbonate solution (KRB), 0.5% albumin, pH 7.4, containing 3.3 mmol/l glucose. At the end of this period, medium was completely removed and replaced by KRB containing either 3.3 mmol/l glucose, 16.7 mmol/l glucose, 3.3 mmol/l glucose plus 20 mmol/l arginine, or 3.3 mmol/l glucose plus 100 micromol/l glibenclamide. After additional 45 min incubation, medium was removed. The media (500 microl) were stored at -20degreesC until insulin concentrations were measured by immuno-radiometric assay (IRMA, Pantec Forniture Biomediche, Turin, Italy). Insulin secretion in response to the different secretagogues in islets from non-diabetic and diabetic islets is described in Table 1.
###end p 16
###begin title 17
###xml 72 77 <span type="species:ncbi:9606">human</span>
Insulin secretion in response to glucose, arginine and glibenclamide in human non-diabetic and diabetic pancreatic islets cultured in vitro.
###end title 17
###begin p 18
SI is the insulin stimulation index i.e. incremental folds above baseline insulin release. Results are mean+/-SEM.
###end p 18
###begin title 19
Analysis of calpain-10 mRNA levels in pancreatic islets
###end title 19
###begin p 20
###xml 162 165 162 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
###xml 167 170 167 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-DelGuerra1">[19]</xref>
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:9606">Human</span>
Total RNA was extracted from human islets, after 3 days in culture, using the RNeasy Protect Mini Kit (Qiagen Inc, Valencia, CA) and quantified by absorbance at A260/A280 (ratio>1.65) nm in a Perkin-Elmer spectrophotometer, and its integrity was assessed after electrophoresis in 1.0% agarose gels by ethidium bromide staining. Human calpain-10 mRNA levels were quantified by Reverse Transcription followed by Real-Time Quantitative RT-PCR [19]. Gene-specific probe and primer pair for calpain-10 (Assays-on-demands, Assay ID Details:
###end p 20
###begin p 21
Hs01550166_m1, Applied Biosystems, Foster City, CA) was used. Each sample was run in duplicates and the transcript quantity was normalized to the mRNA level of cyclophilin A (Applied Biosystems, Foster City, CA).
###end p 21
###begin title 22
Genotyping
###end title 22
###begin p 23
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 414 439 414 439 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCG CTC ACG CTT GCT-3&#8242;</named-content>
###xml 456 491 456 491 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCT CAC CAA GTC AAG GCT TAG C-3&#8242;</named-content>
###xml 501 534 501 534 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;(VIC)-AAG TAA GGC GTT TGA AG-3&#8242;</named-content>
###xml 544 577 544 577 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;(FAM)-AAG TAA GGC ATT TGA AG-3&#8242;</named-content>
###xml 609 633 609 633 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCA GGG CGC TCA CG-3&#8242;</named-content>
###xml 650 685 650 685 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCT CAC CAA GTC AAG GCT TAG C-3&#8242;</named-content>
###xml 695 728 695 728 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;(VIC)-CCT TAC TTC GCA GCA AG-3&#8242;</named-content>
###xml 738 771 738 771 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;(FAM)-CCT TAC TTC ACA GCA AG-3&#8242;</named-content>
Genomic DNA was extracted from pancreatic islets using Wizard Genomic DNA Purification kit (Promega). Two polymorphisms, SNP-43 (rs3792267) and SNP-44 (rs2975760) of the CAPN10 gene, were genotyped using an Allelic Discrimination assay performed with an ABI 7900 system (Applied Biosystems, Foster City, CA). Primers and probes were designed using Assay by Design (Applied Biosystems); SNP-43 (G/A) forward primer 5'-GCG CTC ACG CTT GCT-3', reverse primer 5'-CCT CAC CAA GTC AAG GCT TAG C-3', probe-1 5'(VIC)-AAG TAA GGC GTT TGA AG-3', probe-2 5'(FAM)-AAG TAA GGC ATT TGA AG-3'and SNP-44 (C/T) forward primer 5'-GCA GGG CGC TCA CG-3', reverse primer 5'-CCT CAC CAA GTC AAG GCT TAG C-3', probe-1 5'(VIC)-CCT TAC TTC GCA GCA AG-3', probe-2 5'(FAM)-CCT TAC TTC ACA GCA AG-3'.
###end p 23
###begin title 24
Statistical methods
###end title 24
###begin p 25
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Differences in calpain-10 mRNA levels and insulin secretion between the different groups studied were analyzed using non-parametric Mann-Whitney test and multivariate regression analysis with adjustments for age, sex and BMI. The significance of differences in expression and insulin secretion between genotypes was analyzed using one-way ANOVA, followed by Kruskal-Wallis Z test. All P values were two-tailed and P values less than 0.05 were considered significant. Statistical calculations were performed by NCSS software (NCSS Statistical Software, Kaysville, UT).
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 168 169 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 179 186 175 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1a</bold>
###xml 179 186 175 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006558-g001"><bold>Fig. 1a</bold></xref>
###xml 580 581 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 689 690 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 702 703 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 727 734 723 730 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 727 734 723 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006558-t002"><bold>Table 2</bold></xref>
###xml 933 934 919 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1105 1106 1085 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1207 1214 1187 1194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 1207 1214 1187 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006558-t002"><bold>Table 2</bold></xref>
###xml 1305 1311 1285 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 1386 1393 1366 1373 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 1386 1393 1366 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006558-t002"><bold>Table 2</bold></xref>
###xml 1516 1517 1496 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1526 1527 1506 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1538 1545 1518 1525 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1b</bold>
###xml 1538 1545 1518 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006558-g001"><bold>Fig. 1b</bold></xref>
###xml 1579 1580 1559 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1589 1590 1569 1570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1616 1617 1596 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1626 1627 1606 1607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1760 1761 1740 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1770 1771 1750 1751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1946 1947 1926 1927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1957 1958 1937 1938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2049 2050 2029 2030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2059 2060 2039 2040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 361 366 <span type="species:ncbi:9606">human</span>
The mRNA level of calpain-10 was increased in pancreatic islets from patients with T2D compared with non-diabetic donors (1.87+/-0.26 n = 10 versus 1.14+/-0.12 n = 34; P = 0.01) (Fig. 1a). Since the diabetic donors were significantly older and had higher BMI than control donors, we further tested if these factors might also relate to calpain-10 expression in human islets using a multivariate regression analysis including age, sex, BMI and disease status as covariates. Only disease status was significantly associated with calpain-10 expression in this analysis (beta = 0.66; P = 0.04). Neither SNP-43 nor SNP-44 were associated with calpain-10 mRNA expression in non-diabetic donors (P = 0.32 and P = 0.58, respectively) (Table 2). However, there was an association between SNP-43 and glucose stimulated insulin secretion (GSIS) (G/G 0.072+/-0.013 n = 20, G/A 0.088+/-0.016 n = 13, A/A 0.10+/-0.026 n = 5, microU/islet/minutes; P = 0.022) and the insulin stimulation index (SI; incremental folds above baseline insulin release) (G/G 1.91+/-0.25 n = 20, G/A 2.23+/-0.31 n = 13, A/A 2.43+/-0.49 n = 5; P = 0.04) for a dominant model in response to 16.7 mmol/l glucose in islets from non-diabetic donors (Table 2). In contrast to glucose-stimulated insulin secretion, there was no effect of SNPs in the CAPN10 gene on arginine- or glibenclamide-stimulated insulin secretion in vitro (Table 2). In non-diabetic donors the mRNA level of calpain-10 correlated positively with insulin release in response to arginine (r = 0.45; P = 0.015) (Fig. 1b) but not in response to glucose (r = 0.20; P = 0.3) or glibenclamide (r = 0.22; P = 0.26). However, the correlation between calpain-10 expression and insulin release in response to arginine was lost in T2D donors (r = 0.09; P = 0.8). Although not significant, while the correlation between calpain-10 expression and the level of apoptosis was negative in a subset of islets from non-diabetic donors (r = -0.31; P = 0.27, n = 14), the correlation was positive in a subset of islets from diabetic donors (r = 0.54; P = 0.27, n = 6).
###end p 27
###begin title 28
###xml 26 31 <span type="species:ncbi:9606">human</span>
Calpain-10 mRNA levels in human pancreatic islets are influenced by type 2 diabetes (a) and correlates with arginine-stimulated insulin release in non-diabetic islets (b).
###end title 28
###begin p 29
SI is the insulin stimulation index i.e. incremental folds above baseline insulin release. Results are expressed as mean+/-SEM.
###end p 29
###begin title 30
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 159 164 <span type="species:ncbi:9606">human</span>
Association between SNP-43 and SNP-44 of the CAPN10 gene and calpain-10 mRNA expression, glucose-, arginine- and glibenclamide-stimulated insulin secretion in human non-diabetic pancreatic islets cultured in vitro.
###end title 30
###begin p 31
###xml 214 220 214 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">method</xref>
Basal insulin secretion is analysed when culturing islets in 5.5 mmol/l glucose. Glucose stimulated insulin secretion (GSIS) is analysed after culturing islets in 16.7 mmol/l glucose for 45 min as described in the method section.
###end p 31
###begin p 32
microU/islet/minutes. SI is the insulin stimulation index i.e. incremental folds above baseline insulin release. Results are mean+/-SEM with number of individuals shown in parentheses.
###end p 32
###begin p 33
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
For a dominant model. P values are not corrected for multiple testing.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 106 114 <span type="species:ncbi:9606">patients</span>
The key results from this study were that 1) calpain-10 mRNA levels were elevated in pancreatic islets of patients with type 2 diabetes and 2) there was a positive correlation between calpain-10 expression and insulin release in response to arginine in non-diabetic but not in diabetic donors.
###end p 35
###begin p 36
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 387 389 387 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 741 745 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Turner1">[21]</xref>
###xml 798 802 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Parnaud1">[13]</xref>
###xml 804 808 801 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Johnson1">[16]</xref>
###xml 1032 1036 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Marshall1">[14]</xref>
###xml 1216 1220 1213 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Marshall1">[14]</xref>
###xml 1470 1472 1467 1469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2038 2045 2035 2042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2071 2079 2068 2076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 871 876 <span type="species:ncbi:9606">human</span>
###xml 1368 1373 <span type="species:ncbi:9606">human</span>
###xml 1693 1701 <span type="species:ncbi:9606">patients</span>
CAPN10 was the first gene linked to T2D risk through positional cloning (2). Though the intimate mechanisms for such linkage are not totally clear yet, implications for a role of calpain-10 in insulin action and secretion are plausible. Calpains are Ca2+ dependent cystein proteases that catalyze the cleavage of specific substrates and thereby regulate biological pathways. Moreover, Ca2+ plays an important role in insulin release from beta-cells in response to secretagogues. Since calpain-10 has been implicated in the pathogenesis of T2D, it may be an important regulator of insulin secretion. Indeed, calpain-10 has been suggested to play a role in facilitating the actin reorganization required for glucose-stimulated insulin release [21] and inhibition of calpains blocks insulin secretion [13], [16]. In line with our data, calpain-10 was recently identified in human pancreatic islets and there was a positive correlation between calpain-10 levels and insulin release in response to a secretagogue cocktail in INS-1 cells [14]. Marshall et al also suggested that calpain-10 is involved in the first phase exocytosis and that it binds to the plasma membrane SNARE complex and may affect SNAP-25 proteolysis [14]. In agreement with this suggestion we observed a positive correlation between calpain-10 expression and insulin release in response to arginine in human non-diabetic islets. One could speculate that an arginine dependent increase in intracellular Ca2+ stimulates the activity of calpain-10, which then binds to the SNARE complex and regulates insulin release. However, the correlation between calpain-10 and insulin release in response to arginine was lost in islets from patients with T2D, where calpain-10 expression was elevated by 64% compared with non-diabetic islets. This is difficult to translate to the clinical condition because although first phase insulin secretion is characteristically lost in the very early stages of T2DM, arginine response is usually retained. Whether other factors may be operative in vivo, that are missing in the in vitro situation remains to be ascertained. The loss of correlation between calpain-10 expression and arginine-stimulated insulin secretion in diabetic donors could also be due to the small number of donors in this group. Nevertheless, we cannot exclude that the different response to arginine as a function of calpain-10 expression may reflect a true defect between diabetic and non-diabetic islets. Interestingly, calpain-10 has been suggested to induce apoptosis in response to fatty acids (16). It may, therefore, be possible that calpain-10 has a positive effect on insulin secretion of healthy islets, whereas it may enhance lipotoxic activation of apoptosis in T2D islets effecting overall insulin secreting function. Indeed, although not significant, the opposite correlations between calpain-10 expression and the level of apoptosis in islets from non-diabetic and diabetic donors support this hypothesis. However, this theory needs to be explored further in future studies.
###end p 36
###begin p 37
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 156 159 156 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Horikawa1">[2]</xref>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAPN10</italic>
###xml 837 845 837 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 984 988 984 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Tripathy1">[15]</xref>
###xml 990 994 990 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Stumvoll1">[22]</xref>
###xml 1239 1243 1239 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006558-Tripathy1">[15]</xref>
###xml 479 484 <span type="species:ncbi:9606">human</span>
###xml 815 820 <span type="species:ncbi:9606">human</span>
Combinations of genetic and environmental factors influence the susceptibility to T2D. CAPN10 was the first T2D gene to be identified by positional cloning [2] and some studies have then replicated this association. Although, we and others found associations between polymorphisms in the CAPN10 gene and its expression in skeletal muscle and adipose tissue, the present study was unable to detect a significant association between SNP-43 and SNP-44 and calpain-10 mRNA levels in human pancreatic islets. It is indeed possible that these SNPs do not influence gene expression in islets. On the other hand, our analysis only included islets from 34 non-diabetic donors so we may not have had enough power to detect an association. Nevertheless, there was a nominal association between SNP-43 and insulin release from human islets cultured in vitro in response to glucose. Although, previous studies have found associations between the G/G variant and elevated insulin secretion in vivo [15], [22], the enhanced insulin secretion could represent a compensatory response to decreased insulin sensitivity. Indeed, the association between SNP-43 and insulin secretion in vivo was lost when insulin secretion was adjusted for insulin sensitivity [15]. However, one can not exclude that in vitro studies give different results compared with in vivo analysis.
###end p 37
###begin p 38
###xml 105 110 <span type="species:ncbi:9606">human</span>
In conclusion, our data suggest a contribution of calpain-10 expression on insulin secretory function in human isolated pancreatic islets. Whether the loss of an association between calpan-10 expression and arginine-stimulated insulin release documented in T2D islets reflects a specific pathophysiologic aspect will require further studies.
###end p 38
###begin p 39
###xml 71 76 <span type="species:ncbi:9606">human</span>
We are grateful to prof. Piero Marchetti for the generous provision of human islets and to prof. Stefano Del Prato for critical reading of the manuscript.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Genome-wide association studies provide new insights into type 2 diabetes aetiology.
###end article-title 41
###begin article-title 42
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus.
###end article-title 42
###begin article-title 43
Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses.
###end article-title 43
###begin article-title 44
Linkage of calpain 10 to type 2 diabetes: the biological rationale.
###end article-title 44
###begin article-title 45
Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians.
###end article-title 45
###begin article-title 46
Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom.
###end article-title 46
###begin article-title 47
Calcium-activated neutral protease (calpain) system: structure, function, and regulation.
###end article-title 47
###begin article-title 48
Calpains play a role in insulin secretion and action.
###end article-title 48
###begin article-title 49
Genetic and nongenetic regulation of CAPN10 mRNA expression in skeletal muscle.
###end article-title 49
###begin article-title 50
Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels.
###end article-title 50
###begin article-title 51
A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance.
###end article-title 51
###begin article-title 52
A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin.
###end article-title 52
###begin article-title 53
Inhibition of calpain blocks pancreatic beta-cell spreading and insulin secretion.
###end article-title 53
###begin article-title 54
Evidence that an isoform of calpain-10 is a regulator of exocytosis in pancreatic beta-cells.
###end article-title 54
###begin article-title 55
Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes.
###end article-title 55
###begin article-title 56
RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets.
###end article-title 56
###begin article-title 57
Variation in the calpain-10 gene is associated with elevated triglyceride levels and reduced adipose tissue messenger ribonucleic acid expression in obese Swedish subjects.
###end article-title 57
###begin article-title 58
###xml 37 42 <span type="species:ncbi:9606">human</span>
Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion.
###end article-title 58
###begin article-title 59
###xml 57 62 <span type="species:ncbi:9606">human</span>
Functional and molecular defects of pancreatic islets in human type 2 diabetes.
###end article-title 59
###begin article-title 60
###xml 70 78 <span type="species:ncbi:9606">patients</span>
The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients.
###end article-title 60
###begin article-title 61
Calpain facilitates actin reorganization during glucose-stimulated insulin secretion.
###end article-title 61
###begin article-title 62
Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans.
###end article-title 62
###begin p 63
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 63
###begin p 64
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This investigation was supported by grants from Region Skane Wallenberg, Malmo University Hospital, the Diabetes Programme at Lund University, Novo Nordisk, Crafoord, Bergvall, Wiberg, Pahlsson, Hains, and Linne grant (B31 5631/2006) and grant 522-2006-6480 from the Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 64

